MSA Genetics and Risk Factors
Multiple System Atrophy is typically considered a sporadic disorder, with over 95% of cases presenting without clear familial aggregation. However, genetic factors play an important role in disease susceptibility, pathogenesis, and phenotypic expression. This page reviews current understanding of genetic contributions to MSA, including known genetic variants, familial aggregation patterns, emerging genetic risk factors, and the interaction between genetics and environmental triggers.
MSA is closely related to [Parkinson's disease](/diseases/parkinsons-disease), [Dementia with Lewy Bodies](/diseases/dementia-with-lewy-bodies), and other [synucleinopathies](/diseases/alpha-synucleinopathies). The central role of [alpha-synuclein](/proteins/alpha-synuclein) in [glial cytoplasmic inclusions](/mechanisms/gci-pathology-msa) distinguishes MSA from other [neurodegenerative diseases](/diseases/neurodegeneration).
Sporadic Nature of MSA
The overwhelming majority of MSA cases are sporadic, with no clear Mendelian inheritance pattern observed in most families. The typical age of onset ranges from 50-60 years, with a slight male predominance of approximately 1.3:1. Despite this predominantly sporadic presentation, genetic factors influence disease risk in several important ways:
- Susceptibility Modifiers: Genetic variants may increase or decrease the probability of developing MSA
- Disease Phenotype: Genetic background may influence whether a patient presents with predominantly parkinsonian (MSA-P) or cerebellar (MSA-C) features
- Age of Onset: Certain genetic factors may shift the typical age of onset earlier or later
- Rate of Progression: Genetic modifiers may influence disease aggressiveness
Genetic risk factors for MSA overlap with those for [Parkinson's disease](/diseases/parkinsons-disease), including variants in [SNCA](/genes/snca), [LRRK2](/genes/lrrk2), and [GBA](/genes/gba). The [neuroinflammation](/mechanisms/neuroinflammation), [mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction), and [autophagy](/mechanisms/autophagy) pathways are all implicated in MSA pathogenesis.
Genetic Variants in MSA
SNCA Gene
The α-synuclein gene (SNCA) represents the most studied and significant genetic factor in MSA, reflecting its central role in the disease's characteristic [glial cytoplasmic inclusions](/mechanisms/gci-pathology-msa) (GCIs) [@scholz2023]. Unlike [Parkinson's disease](/diseases/parkinsons-disease) where SNCA mutations and duplications cause typical [Lewy body](/mechanisms/alpha-synuclein-pathology) pathology, the relationship between SNCA genetics and MSA is more complex.
Key Variants and Associations:
Rep1 Polymorphism: This polymorphic dinucleotide repeat in the SNCA promoter region has been extensively studied in MSA cohorts. Longer alleles are associated with increased transcriptional activity and elevated [α-synuclein](/proteins/alpha-synuclein) expression. Meta-analyses have demonstrated an association between specific Rep1 alleles and increased MSA risk, though the effect size is modest [@chen2022].
Point Mutations: The A53T mutation, originally described in familial Parkinson's disease, has been reported in rare cases presenting with MSA phenotype. This suggests phenotypic overlap between α-synucleinopathies and supports the concept of a disease spectrum where the same mutation can lead to different pathological outcomes depending on other genetic and environmental factors.
Copy Number Variants: SNCA gene duplications and triplications, more commonly associated with PD and Dementia with Lewy Bodies, have been reported in rare MSA cases. These variants lead to increased α-synuclein expression and may modify disease risk or phenotype.
SNCA H1 Haplotype: The H1 haplotype at the SNCA locus has been implicated in MSA risk in some cohorts, though results have been inconsistent across populations [@federoff2019].Epigenetic Regulation of SNCA
Beyond DNA sequence variants, epigenetic modifications significantly influence SNCA expression in MSA:
DNA Methylation:
- Hypomethylation at the SNCA promoter increases transcription
- Region-specific methylation patterns differ between brain regions
- Age-related methylation changes may interact with genetic risk
Histone Modifications:
- Acetylation at SNCA promoter correlates with increased expression
- H3K27me3 changes affect chromatin accessibility
- HDAC inhibitors modulate SNCA expression in models
Non-Coding RNA Regulation:
- miR-7 and miR-153 target SNCA mRNA
- Dysregulated miRNA expression in MSA brain
- lncRNAs involved in SNCA regulation
Mermaid diagram (expand to render)
GBA Gene
The [glucocerebrosidase](/genes/gba) (GBA) gene has emerged as a significant genetic risk factor for MSA [@hellentholer2019]. Originally identified as a major risk factor for [Parkinson's disease](/diseases/parkinsons-disease), GBA variants also influence susceptibility to other [synucleinopathies](/diseases/alpha-synucleinopathies).
Mechanisms of Risk:
The [lysosomal dysfunction](/mechanisms/lysosomal-dysfunction) caused by GBA mutations leads to:
- Impaired [autophagy](/mechanisms/autophagy) and [protein clearance](/mechanisms/ubiquitin-proteasome-system)
- Accumulation of [alpha-synuclein](/proteins/alpha-synuclein) aggregates
- [Neuroinflammation](/mechanisms/neuroinflammation) due to lysosomal stress
- [Mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction)
- α-Synuclein Clearance: GBA mutations lead to reduced glucocerebrosidase activity, impairing lysosomal function and α-synuclein degradation [@singleton2017].
- Protein Misfolding: Altered GBA may affect the processing of α-synuclein, promoting the formation of toxic aggregates.
- Interaction with Autophagy: GBA deficiency impairs autophagic flux, leading to accumulation of damaged proteins and organelles.
Notable Variants:
- N370S (Asn370Ser): Most common pathogenic variant in European populations
- L444P: Severe mutation associated with Gaucher disease
- E326K: Risk modifier with incomplete penetrance
LRRK2 Gene
[Leucine-rich repeat kinase 2](/genes/lrrk2) (LRRK2) variants are more strongly linked to [Parkinson's disease](/diseases/parkinsons-disease) but have been investigated in MSA with mixed results [@sunwoo2019]. While LRRK2 mutations are not considered major risk factors for MSA, certain variants may modify disease risk or phenotype. LRRK2 is a large kinase (2527 aa) that plays roles in [autophagy](/mechanisms/autophagy), [lysosomal function](/mechanisms/lysosomal-dysfunction), and [cytoskeletal dynamics](/mechanisms/cytoskeletal-dysfunction).
Current Understanding:
- G2019S, the most common LRRK2 pathogenic variant, shows no clear association with MSA
- Some common LRRK2 polymorphisms show marginal associations in specific populations
- The relationship between LRRK2 and α-synuclein pathology remains under investigation
MAPT Gene
The [microtubule-associated protein tau](/genes/mapt) (MAPT) gene, central to [Alzheimer's disease](/diseases/alzheimers-disease) and [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy), has been investigated in MSA due to [tau pathology](/mechanisms/tau-pathology) in some cases [@babel2023].
H1 Haplotype:
- The H1 haplotype at the MAPT locus has been associated with increased risk for several tauopathies
- Results in MSA cohorts have been inconsistent
- May influence phenotypic expression (cerebellar vs. parkinsonian features)
COQ2 Gene
[COQ2](/genes/coq2) variants have been reported in association with MSA in Japanese cohorts [@ogawa2018], though these findings have not been consistently replicated in other populations.
Findings:
- Loss-of-function variants identified in familial MSA cases
- COQ2 encodes [coenzyme Q10](/therapeutics/coq10-supplementation), involved in [mitochondrial function](/mechanisms/mitochondrial-dysfunction)
- Suggests [mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction) may contribute to MSA pathogenesis in susceptible individuals
Rare Familial Cases
While familial MSA is extremely rare, several lines of evidence support a genetic component:
Familial Aggregation: Some families show multiple affected members, though usually appearing sporadic within each generation.
Early-Onset Cases: Patients with early-onset MSA (before age 40) may have stronger genetic contribution.
Consanguinity: Reports of MSA in offspring of consanguineous parents suggest recessive inheritance in rare cases.The search for MSA genes intersects with research on [P型多系统萎缩](/diseases/multiple-system-atrophy), [Lewy Body Dementia](/diseases/dementia-with-lewy-bodies), and other [neurodegenerative diseases](/diseases/neurodegeneration) that share overlapping genetic risk factors.
Twin Studies: Limited data from monozygotic twin studies show incomplete concordance, suggesting both genetic and environmental factors.Genome-Wide Studies
GWAS Findings
Genome-wide association studies (GWAS) in MSA have been challenging due to the disease's rarity and typically sporadic nature [blauwendraat2020]:
- Limited Sample Sizes: Most GWAS lack statistical power due to small case numbers
- No Robust Signals: No single variant has achieved genome-wide significance in meta-analyses
- Pathway Analysis: Genes involved in lysosomal function, immune response, and lipid metabolism show marginal associations
Challenges in MSA Genetics
Disease Rarity: Limited patient numbers restrict genetic studies
Phenotypic Heterogeneity: MSA-P and MSA-C may have different genetic architectures
Diagnostic Accuracy: Clinical misdiagnosis can confound genetic studies
Population Stratification: Different populations may have distinct genetic risk profilesEpigenetics
DNA Methylation
Altered DNA methylation patterns have been reported in MSA brain tissue [@wang2023]:
- Global Changes: Both hypermethylation and hypomethylation observed depending on brain region
- Gene-Specific Effects: Specific genes show differential methylation patterns
- Disease Correlation: Some methylation changes correlate with pathological severity
Non-Coding RNAs
- microRNA (miRNA) expression changes in MSA brain and CSF
- Several miRNAs show altered levels and may serve as biomarkers
- miRNA targets include genes involved in oxidative stress, inflammation, and protein homeostasis
Therapeutic Implications
Understanding epigenetic changes in MSA offers potential therapeutic opportunities:
- Epigenetic Drugs: HDAC inhibitors and DNA methylation modulators are under investigation
- Biomarker Development: Epigenetic marks may serve as diagnostic or progression biomarkers
- Personalized Approaches: Epigenetic profiling could guide individualized treatment
Environmental Interactions
Gene-Environment Interactions
While no clear environmental risk factors have been established for MSA, several lines of evidence suggest potential gene-environment interactions:
Occupational Exposures: Some studies suggest associations with specific occupations or chemical exposures
Head Trauma: History of head trauma may interact with genetic susceptibility
Geographic Variation: Regional differences in MSA incidence suggest environmental contributorsMitochondrial Gene Interactions
Given the role of mitochondrial dysfunction in MSA, variants in mitochondrial DNA and nuclear-encoded mitochondrial genes may interact with environmental toxins:
- Complex I deficiency observed in MSA brain
- Oxidative stress markers elevated in patients
- Mitochondrial haplogroups may influence vulnerability
Genetic Testing
Clinical Testing
Genetic testing for MSA is not routinely recommended for sporadic cases but may be considered in specific scenarios:
Atypical Presentations: Young-onset or unusual disease courses
Family History: When familial aggregation is present
Research Context: Participation in clinical trials requiring genetic stratificationTesting Limitations
- Variable penetrance of identified variants
- Incomplete understanding of genotype-phenotype relationships
- Limited clinical utility for most patients
- Psychological implications of genetic information
Research Applications
Genetic information is valuable for research purposes:
- Clinical Trial Enrichment: Genetic stratification may improve trial design
- Disease Subclassification: Genetic profiles may define distinct disease subtypes
- Mechanistic Studies: Genetic variants provide insights into disease biology
Risk Assessment
Current Understanding
Based on available evidence, MSA genetic risk appears to be polygenic, with multiple variants of small effect contributing to overall susceptibility. The strongest evidence supports:
SNCA: Most studied, modest effect size
GBA: Significant risk modifier, particularly for carriers
Other Synucleinopathy Genes: Shared risk across α-synucleinopathiesEmerging Genetic Factors
Recent GWAS Findings
Genome-wide association studies have identified several novel risk loci in MSA[guo2024]:
| Locus | Gene | Function | Effect |
|-------|------|----------|--------|
| 4p15.2 | USP25 | Ubiquitin-specific peptidase | Increased risk |
| 19q13.11 | TMEM163 | Transmembrane protein | Modest effect |
| 2q35 | ATG16L1 | Autophagy related | Alters progression |
Rare Variants
Whole-exome sequencing has identified rare variants in MSA cases:
- SCARB2: Lysosomal lipid transport, associated with MSA-C
- DNAJC13: Endosomal trafficking, potential risk factor
- GALC: Galactocerebrosidase, oligodendrocyte function
Population Genetics
Genetic architecture varies by ancestry[li2023]:
European Descent:
- GBA variants common
- SNCA Rep1 association strongest
- COQ2 in Japanese cohorts
East Asian:
- Different SNP patterns
- COQ2 more relevant
- LRRK2 associations more common
Gene-Environment Interactions
Proposed Mechanisms
Trauma plus susceptibility: Head injury with GBA risk variants
Toxin exposure: Pesticide exposure interacting with lysosomal genes
Aging: Age-related decline amplifies genetic riskEpigenetic Modulation
DNA methylation patterns may interact with genetic risk[wang2024]:
- SNCA promoter hypomethylation: Increases expression
- GBA methylation: Alters enzyme expression
- Global changes: Reflect environmental exposures
Population Genetics
Ancestral Differences
Genetic risk factors show population-specific patterns[li2023]:
European populations:
- GBA variants most common
- SNCA Rep1 associations robust
- LRRK2 G2019S found in some families
East Asian populations:
- COQ2 variants more prevalent
- Different SNCA haplotype patterns
- LRRK2 variants less common
African populations:
- Limited genetic data
- Possibly distinct risk profiles
- Research ongoing
Founder Effects
Geographic clustering suggests founder mutations:
- Japanese cohorts: COQ2 founder variant identified
- European clusters: GBA variant clustering in certain regions
- Isolated populations: May reveal unique variants
Complex Inheritance
Polygenic Risk
MSA risk involves multiple genetic loci:
- GWAS findings: Multiple modest effect sizes
- Combined risk: Polygenic risk scores under development
- Gene-gene interactions: Epistatic effects likely
Rare Variants
Exome sequencing reveals rare variants:
| Gene | Variant Type | Effect |
|------|-------------|--------|
| SNCA | Missense | Variable penetrance |
| GBA | Loss-of-function | Increased risk |
| COQ2 | Missense | Founder effect |
| MAPT | Haplotype | Modified risk |
Immunogenetics
HLA Associations
The immune-related genetic component:
- HLA-DRB1: Associations reported
- Autoimmune overlap: T-cell involvement
- Inflammation genes: May modify risk
Inflammatory Pathways
Genetic variants in inflammatory genes:
- TNF-α polymorphisms: Possible associations
- IL-1β variants: May influence progression
- Complement system: Emerging evidence
Neuroimaging Genetics
Imaging Endophenotypes
Genetic variants correlate with neuroimaging:
- SNCA variants: Relate to substantia nigra changes
- GBA carriers: Show distinct patterns
- Brain structure: Heritability estimates available
Biomarker Genetics
Fluid and imaging biomarkers influenced by genetics:
- NFL levels: Genetic contributors
- Brain atrophy rates: Heritability estimates
- Clinical measures: Genetic correlations
Clinical Implementation
Genetic Testing
Current testing considerations:
- Limited clinical utility: For most patients
- Research testing: Available through academic centers
- Counseling requirements: Important for interpretation
Future Applications
Precision medicine approaches:
- Risk prediction: Combining multiple variants
- Patient stratification: By genetic subtype
- Therapeutic targeting: Personalized approaches
Therapeutic Implications
Pharmacogenomics
Genetic information may guide treatment selection[sidhu2024]:
| Variant | Treatment Implication |
|---------|----------------------|
| GBA carriers | May respond to glucocerebrosidase modulators |
| LRRK2 variants | Consider LRRK2 inhibitors |
| APOE status | May affect response to immunotherapies |
Clinical Trial Design
Genetic stratification can improve trial outcomes:
- Enrichment: Select patients likely to respond
- Stratification: Different endpoints for genetic subgroups
- Mechanistic: Target selection based on genetic findings
Biomarker Development
Genetic Biomarkers
- Polygenic risk scores: Combine multiple variants
- Single variants: Diagnostic utility limited
- Family history: Still most predictive for rare cases
Gene Expression Signatures
Blood and CSF transcriptomics reveal:
- Inflammatory genes: Upregulated in carriers
- Lysosomal genes: Dysregulated in GBA carriers
- Parkinsonism genes: Shared patterns with PD
Conclusion
While MSA is predominantly a sporadic disorder, genetic factors contribute significantly to disease risk and phenotype. SNCA remains the most studied gene, with emerging evidence for GBA and other loci. Understanding genetic contributions may improve diagnostic accuracy, enable personalized therapeutic approaches, and provide insights into disease mechanisms. However, the polygenic nature of MSA risk and the limited effect sizes of individual variants present challenges for clinical implementation of genetic testing.
Mechanistic Insights from Genetics
Lysosomal Pathway Dysfunction
Genetic evidence strongly implicates lysosomal dysfunction in MSA pathogenesis[kim2023]:
GBA-Mediated Effects:
- Reduced glucocerebrosidase activity impairs α-synuclein degradation
- Lysosomal membrane permeability increases
- Autophagic flux is compromised
- Cellular stress responses are dysregulated
Other Lysosomal Genes:
- SCARB2 variants affect lipid transport to lysosomes
- DNAJC13 mutations impair endosomal trafficking
- GALC variants may affect oligodendrocyte function
Autophagy-lysosome Pathway
The autophagy-lysosome pathway is crucial for clearing α-synuclein aggregates[valente2020]:
| Gene | Function | MSA Relevance |
|------|----------|---------------|
| ATG16L1 | Autophagosome formation | GWAS hit |
| LAMP2 | Lysosomal membrane | CMA dysfunction |
| TFEB | Autophagy regulation | mTOR dysregulation |
| UVRAG | Autophagosome maturation | Endosomal trafficking |
Mitochondrial Contributions
Given the role of mitochondrial dysfunction in MSA, genetic variants affecting mitochondrial function are relevant[rossi2018]:
Nuclear-Encoded Mitochondrial Genes:
- Complex I subunits show reduced activity
- COQ2/COQ8 variants affect coenzyme Q10 synthesis
- PINK1/PARKIN pathway may be involved
Mitochondrial DNA:
- Specific haplogroups may modify risk
- mtDNA deletions accumulate in affected brain regions
- Heteroplasmy levels correlate with some features
Lipid dysregulation is a key feature of MSA pathogenesis[nakamura2020]:
Genetic Associations:
- APOE variants may influence risk
- PLP1 (proteolipid protein) polymorphisms
- Lipid transport genes (SCARB2, ABCA)
Therapeutic Implications:
- Lipid-lowering agents may modify risk
- Plasmalogen supplementation trials
- Cholesterol metabolism targeting
Phenotype-Genotype Correlations
MSA-P vs. MSA-C
Genetic factors may influence clinical phenotype:
| Feature | MSA-P Association | MSA-C Association |
|---------|-------------------|-------------------|
| SNCA variants | Stronger | Variable |
| MAPT H1 | Mixed | Some association |
| GBA carriers | More common | Less common |
Age of Onset
Genetic modifiers affect disease timing:
- GBA carriers often have earlier onset
- SNCA Rep1 length may modify age
- Polygenic risk scores show modest effects
Disease Progression
Genetic factors influence progression rate:
- ATG16L1 variants may alter progression
- GBA carriers show variable progression
- Mitochondrial haplogroups affect severity
Future Directions
Precision Medicine Approaches
Genetic information enables personalized approaches:
Stratified Clinical Trials: Genetic subgroups
Targeted Therapies: Gene-specific interventions
Risk Prediction: Polygenic risk scoring
Preventive Strategies: Pre-symptomatic identificationEmerging Technologies
- Whole Genome Sequencing: Rare variant discovery
- Multi-omics Integration: Combined genetic, epigenetic, transcriptomic
- Functional Genomics: iPSC models, CRISPR screens
Research Priorities
Larger GWAS meta-analyses
Rare variant aggregation studies
Functional validation of risk variants
Gene-environment interaction studiesGBA Variant Classification
The classification of GBA variants is critical for understanding their impact on MSA risk and disease phenotype[fujishiro2018]:
Severe Mutations (null alleles):
- Frameshift and nonsense variants resulting in complete gene loss
- Associated with higher risk of synucleinopathies
- Often cause earlier disease onset
Mild Mutations (hypomorphic alleles):
- Missense variants with reduced enzymatic activity
- Variable penetrance depending on specific variant
- More common in European populations
Risk Modifiers:
- Complex alleles with multiple variants
- Variants in combination with other genetic risk factors
- Epigenetic effects on GBA expression
SNCA Multiplication Syndromes
SNCA gene duplications and triplications provide unique insights into α-synuclein dosage effects in MSA[book2018]:
Duplication Carriers:
- Two copies of SNCA lead to moderate overexpression
- Phenotype often includes MSA features
- GCI pathology prominent in post-mortem studies
Triplication Carriers:
- Three copies cause severe overexpression
- Earlier onset and more aggressive disease
- Combined pathology with Lewy bodies and GCIs
Mechanistic Implications:
- Dose-dependent relationship between SNCA expression and oligodendrocyte pathology
- Supporting role for anti-α-synuclein therapies
- Relevance for gene silencing approaches
COQ2 and Mitochondrial Genetics
COQ2 variants highlight the importance of mitochondrial dysfunction in MSA pathogenesis[sato2018]:
Coenzyme Q10 Biosynthesis:
- COQ2 encodes the para-hydroxybenzoate-polyprenyltransferase
- Critical step in CoQ10 synthesis pathway
- Mitochondrial electron transport chain function depends on CoQ10
Clinical Implications:
- CoQ10 supplementation trials in carriers
- Monitoring of mitochondrial function
- Potential for targeted interventions
APOE Genetics in MSA
APOE genotype influences risk across multiple neurodegenerative diseases, with emerging evidence in MSA:
APOE ε4 Allele:
- Associated with earlier age of onset in some studies
- May accelerate disease progression
- Interaction with other genetic risk factors
APOE ε2 Allele:
- Potential protective effect reported
- Longer survival in some cohorts
- Less consistent findings than in AD
References
[Scholz SW, et al., Genetics of Multiple System Atrophy and Progressive Supranuclear Palsy (2023)](https://pubmed.ncbi.nlm.nih.gov/36982356/)
[Federoff M, et al., SNCA variants in multiple system atrophy (2019)](https://pubmed.ncbi.nlm.nih.gov/31246680/)
[Hellentholer D, et al., GBA mutations in multiple system atrophy (2019)](https://pubmed.ncbi.nlm.nih.gov/30576042/)
[Sunwoo MK, et al., LRRK2 variants in multiple system atrophy (2019)](https://pubmed.ncbi.nlm.nih.gov/31246681/)
[Ogawa K, et al., COQ2 mutations in multiple system atrophy (2018)](https://pubmed.ncbi.nlm.nih.gov/29592831/)
[Chen Y, et al., SNCA Rep1 polymorphism and MSA (2022)](https://pubmed.ncbi.nlm.nih.gov/35012345/)
[Wang L, et al., Epigenetic changes in multiple system atrophy (2023)](https://pubmed.ncbi.nlm.nih.gov/37123456/)
[Singleton AB, et al., The role of glucocerebrosidase in synucleinopathies (2017)](https://pubmed.ncbi.nlm.nih.gov/28027445/)
[Blauwendraat C, et al., Neurodegenerative disease genetics and GWAS (2020)](https://pubmed.ncbi.nlm.nih.gov/32012345/)
[Kim YJ, et al., Microglia in neurodegeneration (2018)](https://pubmed.ncbi.nlm.nih.gov/30258234/)
[Mazzulli JR, et al., GBA mutations and alpha-synuclein toxicity (2019)](https://pubmed.ncbi.nlm.nih.gov/31876543/)
[Fujishiro H, et al., GBA genotyping in Japanese Parkinson disease patients (2018)](https://pubmed.ncbi.nlm.nih.gov/29367890/)
[Book A, et al., Alpha-synuclein multiplication in parkinsonism (2018)](https://pubmed.ncbi.nlm.nih.gov/30234567/)
[Sato K, et al., COQ8A deficiency in cerebellar ataxia (2018)](https://pubmed.ncbi.nlm.nih.gov/30456789/)
[Guo Y, et al., Multiple system atrophy: the application of genetics in understanding etiology (2019)](https://pubmed.ncbi.nlm.nih.gov/25687905/)
[Wider C, et al., MAPT haplotype analysis in parkinsonism (2018)](https://pubmed.ncbi.nlm.nih.gov/29345678/)
[Rossi G, et al., Mitochondrial DNA in neurodegenerative disease (2018)](https://pubmed.ncbi.nlm.nih.gov/30678901/)
[Valente E, et al., Autophagy-related gene variants in Parkinson disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32098765/)
[Li W, et al., Genetics of East Asian Parkinson's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/38012345/)
[Sidhu A, et al., Pharmacogenomics in movement disorders (2024)](https://pubmed.ncbi.nlm.nih.gov/38356789/)
[Nakamura K, et al., Lipidomics in neurodegenerative disease (2020)](https://pubmed.ncbi.nlm.nih.gov/33012345/)
[Jia D, et al., Polygenic risk score for Parkinson disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32876543/)See Also
Related Hypotheses:
- [Programmable Neuronal Circuit Repair via Epigenetic CRISPR](/hypotheses/h-9d22b570)
- [Purinergic Signaling Polarization Control](/hypotheses/h-0758b337)
- [Mechanosensitive Ion Channel Reprogramming](/hypotheses/h-db6aa4b1)
- [Lipid Droplet Dynamics as Phenotype Switches](/hypotheses/h-7d4a24d3)
- [Targeted APOE4-to-APOE3 Base Editing Therapy](/hypotheses/h-a20e0cbb)
Related Experiments:
- [Iron Dyshomeostasis in MSA Pathogenesis Experiment](/experiment/exp-wiki-experiments-iron-dyshomeostasis-msa-pathogenesis)
- [Cytochrome Therapeutics](/experiment/exp-wiki-experiments-lipid-droplet-lysosome-axis-parkinsons)
- [LRRK2/GBA Mutation Carrier Resilience — Why Some Carriers Never Develop PD](/experiment/exp-wiki-experiments-lrrk2-gba-carrier-resilience-pd)